Xenon stock analysis
Xenon (XENEN) Stock Price & Analysis
XENEN Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- MXN 70.28B
- Enterprise Value
- MXN 5.09B
- Total Cash (Recent Filing)
- MXN 950.80M
- Total Debt (Recent Filing)
- MXN 6.01M
- Price to Earnings (P/E)
- ―
- Beta
- 0.04
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity Runway
The $1.2 billion cash position gives Xenon substantial funding visibility through 2029 under current plans. This supports continued clinical development, AZK launch preparation and early research without requiring near-term financing, reducing dilution and execution pressure over the next several quarters.
AZK Regulatory And Clinical Progress
AZK has advanced from pivotal trials into regulatory review, supported by strong reported seizure-efficacy results. A potential approval and launch would create a path toward commercial revenue, while the clinical data and ongoing studies could support broader epilepsy indications.
Diversified Pain Pipeline
Progress in two distinct non-opioid pain programs broadens Xenon's long-term opportunity beyond AZK and epilepsy. Advancing both candidates into Phase II creates additional clinical value inflection points and provides diversification if any single program encounters development or regulatory setbacks.
Bears Say
No Meaningful Revenue And Large Losses
Xenon has not yet established meaningful commercial scale, and its substantial operating losses show that development spending currently far exceeds revenue generation. Until a product reaches the market and gains adoption, earnings will remain dependent on capital resources rather than internally generated business income.
Heavy Cash Consumption
High and rising cash outflows place continuing demands on Xenon's liquidity despite its strong capitalization. Sustained spending on AZK commercialization and multiple clinical programs could shorten the stated runway if costs increase, trials expand, or commercial revenue arrives later than planned.
Psychiatry Program Uncertainty
The voluntary pause introduces uncertainty around AZK's psychiatry expansion and could limit the program's addressable opportunity if benefit-risk results are not compelling. Future development depends on unblinded X-NOVA2 data and subsequent DSMB and FDA discussions, adding a material clinical decision point.
XENEN FAQ
What is Xenon’s market cap?
When is Xenon’s upcoming earnings report date?
How were Xenon’s earnings last quarter?
Is Xenon overvalued?
Does Xenon pay dividends?
What is Xenon’s EPS estimate?
How many shares outstanding does Xenon have?
What happened to Xenon’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Xenon?
What is the TipRanks Smart Score and how is it calculated?
Xenon Stock Smart Score
Company Description
Xenon
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ian C. Mortimer
- Employees
- 364
- Website
- www.xenon-pharma.com
- Address
- 3650 Gilmore Way, Burnaby, BC, V5G 4W8, CA
Xenon (XENEN) Earnings & Revenues
XENEN Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by the submission of the AZK NDA, strong pivotal focal-seizure efficacy, more than 1,500 patient-years of safety exposure, substantial commercial-launch preparation, positive Phase I data for two pain programs, accelerated X-NOVA2 timing and a $1.2 billion cash balance expected to fund operations into 2029. The main challenges were the voluntary pause in new psychiatry enrollment following neuropsychiatric adverse events, the need to establish the psychiatry benefit-risk profile, the time required for broad payer coverage and one qualified syncope event in the XEN1701 study.
View all MX:XENEN earnings summaries